PDLIM2 and lung adenocarcinoma: PDLIM2 expression was significantly lower in urothelial bladder carcinoma (BLCA), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma, kidney chromophobe, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma, uterine corpus endometrial carcinoma, and thymoma than in adjacent normal tissues.